Final Results
Surgical Innovations Group plc
Preliminary results for the year ended 31 December 2004
22 April 2005
Chairman's Statement
Trading Review
I am delighted to report another year of progress in your Group's overall
performance in 2004.
Group turnover increased from £2.75 million in 2003 to £3.03 million in 2004,
an increase of 10%, which resulted in a 28% increase in pre-tax profit to £
174,000 compared with £136,000 in the previous year.
Earnings before interest, taxation and depreciation ('EBITDA') increased by
55% to £445,000 in 2004 (2003: £287,000). This reflects our significant
investment in tooling and infrastructure in recent years to support our
growing manufacturing requirements. EBITDA of £445,000 is stated after
research and development costs of £330,000, continuing our prudent approach
of writing off these costs as incurred.
An exciting feature of your Group's performance in 2004 is the continuing
growth in products for minimally invasive surgery (MIS), our core business.
Sales of these products accounted for 82% of Group turnover in 2004, compared
with 69% in 2003. This reflects our continually developing relationships with
key internationally renowned strategic partners: Aesculap, Teleflex Medical
and Cardinal Health.
Sales Strategy
As part of our sales strategy, during the last 12 months we have addressed
the need to increase the UK presence of our own branded products. The
strategy has been to instigate a collaborative sales agreement with
established regional independent agents, enabling the Group to sell directly
into all UK hospitals. This also provides an opportunity to promote
additional third-party complementary products. In addition, we have
strengthened our relationships with our two major UK distributors, B Braun
Medical and Mantis Surgical, by enhancing our contractual arrangements.
We are seeking to increase sales through the expansion of our worldwide
distribution network and recently we have signed exclusive distribution
contracts in the Benelux countries and Australia. The Group also continues to
build on its position in the Middle Eastern markets.
Design and Development
As previously reported, the Group is committed to ongoing investment in
product design and development as a key part of maintaining its position at
the forefront of the MIS market. This enables the Group to maintain a
strategic advantage and support valuable relationships with major
international healthcare companies. The Design Team, by utilising their
undoubted skills, has been tasked to seek external projects that contribute
to the growth of the Group. I am pleased to report that in the current year
this initiative has already produced results. For example, the Group has been
awarded development contracts for the use of its technology in aero-engine
maintenance, which could potentially open up a new income stream.
An area that is receiving ever-growing media and government attention is that
of obesity and its social and economic costs to society. As the pressure to
aid the morbidly obese increases, there will be growth in the number of
bariatric ('anti-obesity') cases which involve gastric banding or stomach
stapling. We provide specialist products in this field and are examining ways
in which we can increase our product portfolio in this potentially lucrative
area.
Increasing Profile
Your Board does not feel that the Group's value and growth record over the
past six years is reflected in its share price. Therefore we are investing in
a financial public relations campaign, targeted at the financial investment
community, particularly institutions that operate in the small-cap
marketplace. We continue to actively seek strategic alliances, mergers and
acquisitions and are aware of the need to have our progress reflected in
increased shareholder value.
Prospects
Last year, I concluded by saying that we approach 2004 with optimism for
future growth in sales and profitability. I am delighted that my optimism was
justified and 2005 has commenced with a strong order book. I am confident of
further growth throughout the year.
Finally, on your behalf, I wish to thank my Board colleagues and employees
for their continued dedication and commitment.
Doug Liversidge CBE
21 April 2005
Consolidated Profit and Loss Account
For the year ended 31 December 2004
Notes 2004 2003
£'000 £'000
Turnover (including Royalties) 3,032 2,750
Cost of sales (1,432) (1,312)
Gross profit 1,600 1,438
Administrative expenses (1,358) (1,255)
Operating profit 242 183
Interest payable (68) (47)
Profit on ordinary activities before taxation 174 136
Tax on profit on ordinary activities 38 3
Retained profit 212 139
Earnings per ordinary share 2 0.08p 0.05p
Consolidated Balance Sheet
As at 31 December 2004
2004 2003
£'000 £'000 £'000 £'000
Fixed assets
Tangible assets 811 892
Current assets
Stocks 881 721
Debtors 1,215 1,245
Cash at bank 1 -
2,097 1,966
Creditors: amounts falling due (1,043) (1,111)
within one year
Net current assets 1,054 855
Total assets less current 1,865 1,747
liabilities
Creditors: amounts falling due (215) (352)
after more than one year
Net assets 1,650 1,395
Capital and reserves
Called up share capital 2,580 2,559
Share premium account 16,070 16,048
Capital reserve 329 329
Accumulated losses (17,329) (17,541)
(930) (1,164)
Shareholders' funds 1,650 1,395
Consolidated Cash Flow Statement
For the year ended 31 December 2004
Notes 2004 2003
£'000 £'000 £'000 £'000
Net cash inflow from operating 3 130 265
activities
Returns on investments and
servicing of finance
Interest payable on finance (29) (23)
leases
Interest payable on bank (32) (17)
overdrafts
Interest payable on (7) (7)
convertible loan notes
Net cash outflow from returns (68) (47)
on investments and servicing
of finance
Taxation 18 37
Capital Expenditure: purchases (21) (158)
of tangible fixed assets
Net cash inflow before 59 97
financing
Financing
Issue of share capital 21 -
Receipts from borrowings 22 -
Capital repayments under bank (7) (3)
loans
Capital repayment under (96) (63)
finances
Net cash outflow from (60) (66)
financing
(Decrease)/increase in cash 4 (1) 31
Notes
For the year ended 31 December 2004
1. Accounting policies
The principal accounting policies which remain unchanged from the
previous year, are as follows:
a) Basis of accounting
The financial statements have been prepared under the historical
cost basis of accounting and in accordance with applicable
Accounting Standards in the United Kingdom.
b) Basis of consolidation
The Group financial statements consolidate those of the Company and
of its subsidiary undertakings drawn up to 31 December 2004. The
results of subsidiaries accounted for under the acquisition
accounting method are included in the consolidated profit and loss
from the date of their acquisition. The results of subsidiaries,
accounted for under the merger accounting method, are included in
the consolidated profit and loss account as if they had always been
part of the Group. Intra-Group sales and results are eliminated on
consolidation and all sales and results relate to external
transactions only.
2. Earnings per ordinary share
The earnings per ordinary share has been calculated by dividing the
profit attributable to ordinary shareholders for the year ended 31
December 2004 of £212,000 (2003 : £139,000) by the weighted average
number of ordinary shares in issue during the year of 256,955,941 (2003 :
255,659,894) and amounted to 0.08p per share (2003 : 0.05p per share).
The Group has two categories of dilutive potential ordinary shares, those
share options granted where the exercise price is less than the average
price of the Company's ordinary shares during the year and the remaining
convertible loan notes. The dilution has no effect on basic earnings per
share.
3. Reconciliation of operating profit to net cash inflow from operating
activities
2004 2003
£'000 £'000
Operating profit 242 183
Depreciation of tangible fixed assets 203 104
Increase in stocks (160) (159)
Decrease/(increase) in debtors 50 (206)
(Decrease)/increase in creditors (205) 343
Net cash inflow from operating activities 130 265
4. Reconciliation of net cash flow to movement in net debt
2004 2003
£'000 £'000
(Decrease)/increase in cash in the year (1) 31
Cash outflow from finance leases and loans 103 66
Change in net debt resulting from cash flows 102 97
New finance leases and loans (101) (178)
Movement in net debt 1 (81)
Net debt at beginning of year (640) (559)
Net debt at end of year (639) (640)
5. Analysis of changes in net debt
At Cash flow Non-cash At
1 January changes 31 December
2004 2004
£'000 £'000 £'000 £'000
Cash at bank and in hand - 1 - 1
Bank overdrafts (173) (2) - (175)
(1)
Bank loan (5) 7 (22) (20)
Finance leases (352) 96 (79) (335)
103
Convertible loan notes (110) - - (110)
(640) 102 (101) (639)
6. The Annual General Meeting of the Company will be held at the Village
Hotel and Leisure Club, 186 Otley Road, Headingley Leeds LS16 5PR at
3.00pm on Tuesday, 28 June 2005.
7. The foregoing statements do not constitute the Group's statutory accounts.
The Group's statutory accounts, on which the Group's auditors, Grant
Thornton LLP, have given an unqualified opinion in accordance with Section
235 of the Companies Act 1985, are to be delivered to the Registrar of
Companies and will be posted to shareholders shortly. Additional copies of
the annual report and of this announcement will be available at the
Company's registered office: Clayton Park, Clayton Wood Rise, Leeds, LS16
6RF.
Enquiries:
Surgical Innovations Group plc
Graham Bowland, Finance Director Tel: +44 (0) 113 230 7597
Westhouse Securities LLP
Tim Feather Tel: +44 (0) 161 838 9140